US 12,241,067 B2
Compounds and methods for reducing LRRK2 expression
Tracy A. Cole, Encintas, CA (US); and Susan M. Freier, San Diego, CA (US)
Assigned to Ionis Pharmaceuticals, Inc., Carlsbad, CA (US)
Filed by Ionis Pharmaceuticals, Inc., Carlsbad, CA (US)
Filed on Nov. 29, 2023, as Appl. No. 18/523,746.
Application 18/523,746 is a continuation of application No. 17/712,822, filed on Apr. 4, 2022, granted, now 11,873,495.
Application 17/712,822 is a continuation of application No. 16/972,822, granted, now 11,332,746, issued on May 17, 2022, previously published as PCT/US2019/039558, filed on Jun. 27, 2019.
Claims priority of provisional application 62/690,790, filed on Jun. 27, 2018.
Prior Publication US 2024/0360453 A1, Oct. 31, 2024
Int. Cl. C12N 15/11 (2006.01); A61K 31/7125 (2006.01); A61K 47/02 (2006.01); A61K 47/46 (2006.01); A61P 25/16 (2006.01); C12N 15/113 (2010.01)
CPC C12N 15/1137 (2013.01) [A61K 31/7125 (2013.01); A61K 47/02 (2013.01); A61K 47/46 (2013.01); A61P 25/16 (2018.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/3341 (2013.01); C12N 2310/341 (2013.01); C12N 2310/346 (2013.01); C12N 2310/3525 (2013.01)] 25 Claims
 
1. A modified oligonucleotide according to the following formula:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
(SEQ ID NO: 3385) or a salt thereof.